Dow Jones 30 Stocks SEC Filings — April 28, 2026

28-04-2026

Maravai LifeSciences Holdings, Inc. (MRVI) filed a DEFA14A proxy statement detailing its board structure, reduced from 11 to 8 directors since the 2025 annual meeting, with Class III directors (Bernd Brust, Gregory T. Lucier, Luke Marker) up for election to serve until 2029. The filing outlines deadlines for 2027 Annual Meeting shareholder proposals (December 25, 2026 for Rule 14a-8 inclusion) and nominations (by close of business February 25, 2027). It also describes the Director Nomination Agreement providing GTCR entities with board nomination rights scaled to ownership levels (e.g., 100% if >=40% of IPO ownership).

• ·Shareholder proposals under Rule 14a-8 for 2027 AGM inclusion must be received no later than December 25, 2026.
• ·Director nomination notices (not for proxy inclusion) due by close of business February 25, 2027 (not earlier than January 26, 2027).
• ·Universal proxy rule notice for competing nominees due by March 27, 2027.
• ·Ratification of Deloitte & Touche LLP as auditor for year ending December 31, 2026 is a routine matter allowing broker discretionary voting.
• ·Ages of directors as of March 27, 2026: Bernd Brust (59), Gregory T. Lucier (61), Luke Marker (41), Susannah Gray (65), R. Andrew Eckert (64), Constantine Mihas (59), Sean Cunningham (50), John DeFord (64).

28-04-2026

RE/MAX Holdings, Inc. entered into a Merger Agreement on April 26, 2026, with The Real Brokerage Inc. and affiliates to form Real REMAX Group as the new holding company, where Company shareholders can elect 5.150 shares of Real REMAX Group common stock or $13.80 cash per share (prorated to $60M-$80M total cash), and Parent shareholders will own ~59% of the combined entity versus ~41% for Company shareholders at midpoint. The board unanimously recommends approval, with closing subject to stockholder votes, regulatory approvals including HSR, Nasdaq listing, and court orders, targeting Nasdaq listing post-merger. Termination fees include $25M from Company or $31M from Parent under certain conditions, plus a $36M regulatory fee from Parent if applicable.

• ·Stock Election Exchange Ratio of 5.150 shares adjusted by 10-for-1 Parent share consolidation.
• ·End Date for closing: 9 months from agreement execution, with two 45-day extensions possible if non-regulatory conditions met.
• ·Mergers intended to qualify as tax-free reorganization under IRC Section 368(a) and Section 351.
• ·Real REMAX Group Common Stock to list on Nasdaq; Company and Parent shares to be delisted.

28-04-2026

For Q1 2026, Bread Financial Holdings, Inc. reported net income of $181 million, up 32% YoY from $138 million, with net interest income rising 6% to $1,067 million and non-interest expenses declining 1% to $472 million. Earnings per diluted common share surged 50% to $4.15, supported by credit sales growth of 7% to $6,510 million and improved credit metrics including a lower delinquency rate of 5.59%. However, non-interest income worsened to $(49) million from $(36) million due to higher interchange revenue losses, and provision for credit losses increased 2% to $303 million.

• ·Net interest margin improved to 19.25% from 18.06%.
• ·Return on average tangible common equity rose to 27.4% from 23.0%.
• ·End-of-period credit card and other loans increased 2% to $18,135M.
• ·Common equity tier 1 capital ratio strengthened to 13.3% from 12.0%.
• ·Net principal loss rate improved to 7.33% from 8.16%.
• ·Cash from operating activities increased to $487M from $393M.

28-04-2026

Herc Holdings reported Q1 2026 total revenues of $1,139 million, up 32% YoY from $861 million, driven by 33% growth in equipment rental revenue to $981 million following the H&E acquisition; Adjusted EBITDA rose 33% to $448 million with margin flat at 39%. However, the company posted a net loss of $24 million ($0.72 per share), wider than the prior year's $18 million loss, amid higher depreciation, interest expense up to $128 million from $62 million, and dollar utilization declining to 36.4% from 37.6%. Free cash flow nearly doubled to $94 million, and full-year 2026 guidance was affirmed.

• ·Average fleet at OEC increased 36% YoY in Q1 2026.
• ·Net leverage increased to 3.96x from 2.53x YoY.
• ·Liquidity of approximately $1.9 billion as of March 31, 2026.
• ·Quarterly dividend of $0.70 per share declared and paid.
• ·2026 gross capex guidance: $800 million to $1.1 billion.

28-04-2026

Asbury Automotive Group reported Q1 2026 revenue of $4.1 billion and gross profit of $727 million (17.7% margin), with GAAP net income rising 42% YoY to $188 million ($9.87 EPS) driven by a $94 million gain on divestitures of 10 dealerships (annualized revenue $625 million). However, adjusted net income fell 24% YoY to $102 million ($5.37 EPS) after excluding divestiture gains, Tekion implementation costs, weather losses, and other items, while used retail gross profit per unit grew 16% to $1,847. The company repurchased 678,000 shares for $147 million and converted over 50% of stores to Tekion amid ongoing portfolio optimization.

• ·Same store revenue of $3.5 billion and gross profit of $616 million (17.7% margin) in Q1 2026.
• ·Parts and service revenue $627 million with gross profit $365 million; F&I PVR $2,302 total / $2,307 same store.
• ·Adjusted operating margin 5.0% total / 5.3% same store Q1 2026.
• ·Transaction adjusted net leverage ratio 3.2x as of March 31, 2026.
• ·$453 million remaining on share repurchase authorization as of March 31, 2026.

28-04-2026

Coronado Global Resources Inc. reported Q1 March 2026 results with ROM production declining 21.7% QoQ to 5.4 Mt from 6.9 Mt and saleable production down 30.7% QoQ to 3.0 Mt, reflecting planned maintenance, CHPP shutdown at Curragh, longwall moves at Buchanan, weather delays, and Logan idling due to weak High-Vol market. Sales volumes fell 23.2% QoQ to 3.5 Mt, but realised met coal pricing rose 11.2% QoQ to US$165.4/t and overall group pricing increased 9.1% to US$133.2/t; Buchanan doubled EBITDA to US$30M despite challenges, and US$26M was received under revised Stanwell arrangements. Average mining cash costs surged 40.6% QoQ to US$135.3/t due to lower volumes, though expected to improve with higher run-rates.

• ·Logan Complex idled following WARN Act notice due to constrained High-Vol market demand.
• ·Curragh Complex experienced temporary coal recovery constraints from rain after strong overburden removal.
• ·Export sales increased to 74.4% of total group volumes QoQ (+1.2%).
• ·PLV HCC FOB AUS Index averaged US$234.7/t in Mar Q26 (+17.3% QoQ).

28-04-2026

This DEF 14A proxy statement discloses beneficial ownership of Lindblad Expeditions Holdings, Inc. common stock as of April 14, 2026, with 65,499,714 shares outstanding; insiders (16 directors and executives) collectively own 17,079,026 shares (26.1%), led by Sven-Olof Lindblad at 10,675,063 shares (16.3%), while 5% owners include Ariel Investments, LLC (5,524,660 shares, 8.4%) and Capitol Acquisition Management 2 LLC (3,324,820 shares, 5.1%). Stockholders are voting to elect four Class B directors (L. Dyson Dryden, John M. Fahey, Catherine B. Reynolds, Andy Stuart) for terms until the 2029 annual meeting. Two late Section 16(a) filings were noted: one by Sven Lindblad and one by Benjamin Bressler.

• ·Board is staggered into three classes with 11 directors: Class A (4), Class B (4, up for election), Class C (3).
• ·Two delinquent Section 16(a) reports in 2025: Sven Lindblad (April 2, forfeiture of unearned RSUs), Benjamin Bressler (April 15, withholding for taxes on vesting).
• ·Annual meeting voting results to be announced preliminarily at meeting and finalized in Form 8-K within four business days.

28-04-2026

Insight Inv LLC filed its 13F-HR on April 28, 2026, reporting total equity holdings valued at 182747722 USD as of March 31, 2026, across 104 positions all held with sole voting power. Top holdings include Apple Inc (8113666 USD, 31970 shares), First Trust Exchange Traded Fund Rising Dividend Achievers (5863818 USD, 85879 shares), and Corning Inc (5456748 USD, 40132 shares). No prior period comparisons or changes are provided in the filing.

• ·Filing CIK: 0001909322
• ·Business address: 330 Illinois Street, El Segundo, CA 90245
• ·Phone: 310-426-6322

28-04-2026

Christian Angermayer, Chairman of Enhanced Ltd., posted on X promoting the imminent merger with SPAC A Paradise Acquisition Corp. (APAD), highlighting key deadlines: April 29, 2026, for investors to buy shares and elect non-redemption at $10 per share valuation; May 1, 2026, shareholder vote; May 7, 2026, expected closing; and May 8, 2026, trading as ENHA on NYSE. The combined entity will be Enhanced Group Inc., an elite sports and consumer products company focused on Enhanced Games and telehealth. While optimistic about future growth, the filing discloses significant risks including Enhanced's unproven business model, minimal revenue history, regulatory scrutiny, and high redemption risks.

• ·APAD shares trade on Nasdaq until closing, then ENHA on NYSE
• ·Merger proxy and S-4 registration statement available on SEC EDGAR
• ·Contact for documents: The Sun’s Group Center, 29th Floor, 200 Gloucester Road, Wan Chai, Hong Kong, +852 9583 3199

28-04-2026

The SPAC Board unanimously approved the Business Combination Agreement to merge with a target company forming Pubco, a publicly traded XRP treasury vehicle, citing attractive market opportunity, over $1 billion in equity commitments at $10.00 per share, initial XRP holdings of at least 473,276,430 XRP, and a fairness opinion from CCM. Pubco aims to grow via ecosystem participation, yield generation, and NAV-accretive structure, led by experienced executives like Asheesh Birla (CEO). However, risks include SPAC shareholders holding a minority position post-merger, potential high redemptions reducing trust cash below $5,000,001, and uncertainty that projected benefits will be achieved.

• ·Transactions structured as 'Up-C' with Pubco as public corporation and operating company as partnership for tax purposes, allowing in-kind XRP contributions.
• ·Six-month lockup on Pubco Class A and Class C Common Stock for certain Ripple affiliates, Sponsor, and SPAC Insiders.
• ·SPAC financial advisor CCM provided fairness opinion on the Exchange Ratio.

28-04-2026

Topor & Co. Korea filed its quarterly 13F-HR report disclosing $118,249,710 in total holdings across 18 positions as of March 31, 2026. The portfolio is diversified across equity and fixed income ETFs, with top holdings including Vanguard Intl Equity Index F TT WRLD ST ETF ($31,251,053), Vanguard Index Fds S&P 500 ETF ($24,986,553), and iShares TR MSCI ACWI ETF ($18,256,123). No prior period comparisons are available in this filing.

• ·Filing covers period ending March 31, 2026, filed on April 28, 2026
• ·All holdings reported as sole discretionary with zero shared or other voting authority

28-04-2026

Novus Advisors, LLC filed a 13F-HR report disclosing 47 equity holdings totaling $44,702,426 as of March 31, 2026, with 0 changes reported since the prior filing. The portfolio is dominated by ETFs from iShares and SPDR series, including top positions in State Street SPDR S&P 500 ETF Trust ($4,670,748), SPDR S&P 500 ETF ($3,953,275), and SSGA Active Trust State Street US ($3,343,126). Individual stocks such as Exxon Mobil Corp ($709,857), Union Pacific Corp ($597,816), and Amazon.com Inc ($281,164) represent smaller allocations.

28-04-2026

Controladora Vuela Compania de Aviacion, S.A.B. de C.V. (Volaris) discloses 100% equity ownership in five Mexican trusts (Banco Multiva Fidecomisos CIB/3853, 3855, 3866, 3867, 3921) for financing pre-delivery payments under its Airbus aircraft purchase agreement, with Banco Multiva assuming rights from CIBanco effective September 2, 2025. The company also reports 100% ownership in Fidecomiso CIB/3249, through which subsidiary Volaris Opco issued three series of asset-backed securities notes (15 million units each): VOLARCB 19 (Ps.1.5B or $78.5M, fully amortized June 20, 2024), VOLARCB 21L (Ps.1.5B or $72.1M), and VOLARCB 23 (Ps.1.5B or $85.8M), under CNBV-approved programs up to Ps.3.0B ($157.1M/$144.2M) and Ps.5.0B ($286.2M). Two additional 100%-owned administrative trusts (F/745291 and CIB/3081) manage shares.

• ·VOLARCB 19 notes fully amortized on June 20, 2024.
• ·Banco Multiva assumed all rights and obligations of CIBanco effective September 2, 2025.

28-04-2026

Cooper Investors PTY LTD filed its 13F-HR report for the quarter ended March 31, 2026, disclosing holdings in 42 equity positions with a total market value of $245328286. The portfolio includes diversified positions across technology (e.g., Alphabet Inc. Class A at $4216780, Microsoft at $4468322), media (e.g., News Corporation Class A at $39412560), and other sectors, all held with sole voting power. No changes in holdings or voting authority were indicated in the filing.

• ·All 42 positions held with sole shared investment discretion and sole voting power (SH SOLE).
• ·Filing covers period ended 03-31-2026, submitted 04-28-2026.

28-04-2026

Baker Boyer National Bank filed its 13F-HR on April 28, 2026, disclosing total holdings of $332827952 across 119 positions as of March 31, 2026. The portfolio emphasizes ETFs, with the largest positions in DFA U.S. Core Equity 2 ETF ($63332590), DFA World Ex-U.S. Core Equity 2 ETF ($56925839), and Vanguard Muni Bond Tax Exempt ($56226828). Notable individual stock holdings include Microsoft Corp ($7074319), Apple Inc ($4349199 sole), and Paccar Inc ($4216443).

• ·Portfolio includes both sole discretionary (SH SOLE) and defined (SH DFND) holdings.
• ·Filer located in Walla Walla, WA; CIK 0001079398.
• ·No other managers reported (0 managers).

28-04-2026

Ryan Investment Management, Inc. filed a 13F-HR report on April 28, 2026, disclosing its equity holdings as of March 31, 2026, with a total portfolio value of $177829558 across 20 positions, primarily ETFs. Top holdings include iShares MSCI EAFE ETF at $36297870, ProShares Short QQQ ETF at $34302469, ProShares Short S&P500 ETF at $34034020, iShares Russell 1000 Value ETF at $24115865, and State Street SPDR Bloomberg 1-3 Month T-Bill ETF at $11541600. The portfolio features a mix of long equity ETFs, short ETFs, bond ETFs, and one individual stock position in Eli Lilly & Co. valued at $836071.

• ·Filing filed as of April 28, 2026, for period ended March 31, 2026.
• ·All positions reported with sole voting power.
• ·Business address: 22860 Two Rivers Road, Suite 200, Basalt, CO 81621.

28-04-2026

Corvex, Inc. (formerly associated with Movano Inc., ticker MOVE) filed Amendment No. 1 to its 10-K for the fiscal year ended December 31, 2025, on April 28, 2026, pursuant to General Instruction G(3) as it will not file a definitive proxy statement within 120 days of fiscal year-end. The amendment restates Part III items (Directors, Executive Compensation, Security Ownership, Related Transactions, and Accountant Fees), updates the cover page to note no incorporated documents, and adds new certifications, the 2024 Equity Incentive Plan, and a common stock description as exhibits. No financial statements or related disclosures were amended or included.

• ·Entity is a Non-accelerated Filer, Small Business, and Emerging Growth Company.
• ·Entity File Number: 001-40254; CIK: 0001734750; EIN: 82-4233771.
• ·Trading on NASDAQ under symbol MOVE.
• ·Address: 3401 North Fairfax Drive, Suite 3230, Arlington, VA 22226.
• ·Original 10-K filed March 31, 2026.

28-04-2026

Exencial Wealth Advisors, LLC, based in Oklahoma City, OK, filed a 13F-HR reporting total holdings of $3,217,468,970 across 568 positions as of March 31, 2026. Top holdings include Apple Inc. at $114,288,462 (450,327 shares), Dimensional ETF Trust US Small Cap Val at $98,019,900 (2,797,372 shares), and Invesco Exchange Traded FD T S&P500 EQL WGT at $79,667,694 (415,109 shares). No period-over-period comparisons or performance changes are detailed in the filing.

• ·Filing date: April 28, 2026
• ·Report period end: March 31, 2026
• ·SEC file number: 028-15490
• ·Former company name: Burns Wealth Management, Inc. (name change date: May 7, 2013)

28-04-2026

Patriot National Bancorp, Inc. entered into indemnification agreements on April 27, 2026, with directors Anahit Magzanyan, Jonathan Roth, Mario De Tomasi, Carlos P. Salas, and Jeffrey Seabold, providing indemnity for expenses related to their service and advancement of expenses. On April 24, 2026, effective April 26, 2026, the company executed addenda to employment agreements with executives Steven A. Sugarman (President and Bank CEO), Carlos P. Salas (CFO), Angie Miranda (Chief Risk Officer), and William Paul Simmons (Chief Credit Officer), adding severance provisions including cash multiples of compensation, pro rata bonuses, continued health benefits, accelerated equity vesting, and limits on excise taxes under IRC Sections 280G and 4999. These actions were approved by the Compensation Committee and Board of Directors.

• ·Indemnification agreements reference standard form filed as Exhibit 10.1 on December 31, 2024.
• ·Addenda attached as Exhibits 10.1 to 10.4.

28-04-2026

Revolution Medicines, Inc. has filed a DEFA14A proxy statement soliciting proxies for its Annual Meeting of Stockholders scheduled for June 18, 2026, at 7:30 a.m. PDT, held virtually at www.virtualshareholdermeeting.com/RVMD2026. Stockholders are appointing Mark A. Goldsmith, M.D., Ph.D. and Jeffrey Cislini, or either of them, as proxies to vote shares in accordance with Board recommendations if no directions are provided.

• ·Proxy voting available at www.proxyvote.com
• ·Meeting accessible at www.virtualshareholdermeeting.com/RVMD2026

28-04-2026

Valmont Industries reported net sales of $1,029,197 thousand for the thirteen weeks ended March 28, 2026, up 6.2% YoY from $969,314 thousand, with Infrastructure segment at $803,180 thousand and Agriculture at $226,017 thousand. Operating income increased 21.3% to $155,626 thousand, driving net earnings attributable to Valmont of $108,033 thousand (diluted EPS $5.51), up 23.8% YoY. However, cash and equivalents fell $26,951 thousand to $160,189 thousand QoQ amid $57,550 thousand stock repurchases, $34,568 thousand capex, and an $11,195 thousand acquisition.

• ·Diluted EPS $5.51 vs $4.32 YoY (+27.6%)
• ·Cash dividends declared $0.77 per share (vs $0.68 prior year)
• ·131,197 shares repurchased
• ·Redeemable noncontrolling interests reduced to $9,301 thousand after $8,922 thousand purchase
• ·Income taxes paid $7,290 thousand (down from $10,672 thousand YoY)

28-04-2026

CCEP reported Q1 2026 revenue of €5,001 million, up 6.7% as reported and 9.4% comparable FX-neutral from €4,689 million in Q1 2025, supported by strong 8.5% volume growth to 970 million unit cases and higher average daily sales. Europe revenue rose 9.1% to €3,549 million with 1.3% revenue per unit case growth, while APS revenue increased modestly 1.1% to €1,452 million but revenue per unit case declined 0.3%. Overall revenue per unit case grew 0.8% to €5.29 amid 93 consumption days versus 87 prior year.

• ·FX impact on total revenue: +€131 million
• ·FX impact on Europe revenue: +€24 million
• ·FX impact on APS revenue: +€107 million
• ·Total average daily sales: 10.43 million unit cases (Q1 2026) vs 10.27 (Q1 2025), +1.6%

28-04-2026

Johnson & Johnson's 2026 Annual Meeting of Shareholders occurred on April 23, 2026, where all 12 director nominees were elected with strong support (over 1.65 billion shares For each). Shareholders approved the advisory vote on executive compensation and ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. However, the shareholder proposal requiring an independent board chair was rejected, with only 406,353,048 shares For versus 1,326,857,173 Against.

• ·Say-on-pay advisory vote: 1,641,173,032 For, 91,774,923 Against, 9,607,174 Abstained.
• ·Auditor ratification: 1,914,846,474 For, 138,633,899 Against, 3,481,479 Abstained (no non-votes).
• ·Director elections showed some opposition, e.g., J. Duato: 1,654,870,358 For, 84,725,734 Against.
• ·Filing signed April 27, 2026, by Marc Larkins.

28-04-2026

Oversea-Chinese Banking Corp Ltd filed its 13F-HR on April 28, 2026, disclosing US equity holdings as of March 31, 2026, across five managed entities including Bank of Singapore Limited and Great Eastern Life Assurance Company Limited. Key positions include Apple Inc (market value 85421362 DFND 3), Amazon.com Inc (73620032 DFND 3), Broadcom Inc (62090091 DFND 3), Alphabet Inc CAP STK CL A (68725934 DFND 3), and Citigroup Inc (52301063 DFND 1), with additional derivatives like puts on Advanced Micro Devices Inc and calls. No prior period data is provided for comparisons, reflecting a routine quarterly snapshot of significant US market exposure.

• ·Filing covers 5 managed accounts (CIK managers: 028-23120, 028-22959, 028-22904, 028-22827, 028-24129)
• ·Signed in Singapore on April 28, 2026
• ·Includes derivative positions such as puts on Adobe Inc, Alphabet Inc, Amazon.com Inc, and Advanced Micro Devices Inc

28-04-2026

UPS reported Q1 2026 consolidated revenues of $21.2B with operating profit of $1.27B (6.0% margin) and adjusted operating profit of $1.32B (6.2% margin), diluted EPS of $1.02 and adjusted EPS of $1.07. While International segment revenue grew 3.8% to $4,540M, U.S. Domestic revenue declined 2.3% to $14,125M and Supply Chain Solutions revenue fell 6.5% to $2,537M; operating profits declined in U.S. Domestic to $515M (from $979M) and International to $547M (from $641M), though Supply Chain Solutions improved to $205M (from $46M). The company reaffirms FY2026 guidance of approximately $89.7B revenue, 9.6% adjusted operating margin, $3.0B capex, and $5.4B dividends.

• ·GAAP diluted EPS of $1.02; non-GAAP adjusted diluted EPS of $1.07 for Q1 2026, including after-tax transformation charges of $42M ($0.05 per share).
• ·Achieved $600M program cost savings in Q1 2026 from Network Reconfiguration and Efficiency Reimagined; expect $3B full-year savings.
• ·Program costs incurred to date $599M as of March 31, 2026, including $55M in Q1 2026; expected non-GAAP adjusted operating expense exclusion of $1.3B-$1.5B in 2026.
• ·Initiatives expected to conclude by 2027.

28-04-2026

On April 23, 2026, Hilltop Holdings Inc. appointed Dana Bober and Stephen Haworth as independent directors to its Board. Ms. Bober, a former Partner at Ernst & Young LLP with 30 years of audit experience, was appointed to the Audit Committee; Mr. Haworth, Vice Chairman of Flexpoint Ford LLC with 20 years as a CFO in private equity, was appointed to the Audit and Compensation Committees. Each received restricted stock units valued at $200,000, cliff vesting on April 23, 2029.

• ·Dana Bober, age 56, retired from Ernst & Young in June 2025 after serving as Americas Practice Leader, Financial Accounting Advisory Services since 2017.
• ·Stephen Haworth, age 64, previously CFO of Flexpoint Ford LLC from 2005 to 2025 and Partner at Ernst & Young prior to 2005.

28-04-2026

SpringBig Holdings, Inc. received a Notice of Default on April 21, 2026, related to its 2024 Secured Term Notes ($1.6M outstanding) and 2024 Secured Convertible Notes ($8.2M outstanding, maturing January 2027), citing a minimum cash covenant breach in January 2026 (despite subsequent compliance in February and March), alleged failure to consult with Lead Noteholders Shalcor Management, Inc. and Lightbank II, L.P., and disputed litigation representations from April 2025. The Company, current on all payments, disputes the claims and is negotiating solutions in good faith. No acceleration, foreclosure, or other remedies have been exercised by holders as of April 27, 2026.

• ·Minimum cash covenant non-compliance notified for January 2026; compliance certificates provided for February and March 2026
• ·Alleged litigation representations issue from prior notice dated April 3, 2025
• ·Notes maturity: January 2027

28-04-2026

Hilton reported strong Q1 2026 financial results, including net income of $383 million (up 27.7% YoY from $300 million), Adjusted EBITDA of $901 million (up 13.3% YoY from $795 million), and system-wide comparable RevPAR growth of 3.6% YoY driven by gains in occupancy and ADR. The company added 16,300 rooms (net 10,900), grew its development pipeline 5% YoY to 527,000 rooms, and returned $860 million to shareholders via repurchases and dividends. However, Middle East & Africa occupancy declined 4.1 percentage points YoY, and full-year RevPAR outlook is modest at 2.0-3.0% growth amid anticipated lower Middle East RevPAR.

• ·Total revenues $2,937M in Q1 2026 vs $2,695M in Q1 2025.
• ·Franchise and licensing fees $696M in Q1 2026 (+11.4% YoY).
• ·Debt weighted average interest rate 5.00% with no material maturities before April 2027.
• ·Q2 2026 Adjusted EBITDA projected $1,015M-$1,035M.
• ·Portfolio spans 27 brands in 144 countries and territories.

28-04-2026

China Universal Asset Management Co., Ltd. filed its 13F-HR report as of March 31, 2026, disclosing 502 equity holdings with a total market value of $1,320,814,008, all held with sole voting authority. Top positions include NVIDIA Corp ($80,937,655, 464,069 shares), Apple Inc ($61,972,473, 244,188 shares), Microsoft Corp ($49,646,830, 134,119 shares), Alphabet Inc-CL A ($48,822,224, 169,781 shares), and Amazon.com Inc ($42,299,637, 203,100 shares). No period-over-period changes or performance metrics are provided in the filing.

• ·All 502 holdings reported as sole ownership with zero shared discretion or other voting authority.
• ·Filing covers period ended March 31, 2026, submitted April 28, 2026.

28-04-2026

Hallmark Venture Group reported no revenue in 2025, the same as 2024, with net loss narrowing to $126,948 from $672,060 due to a $1,178,162 gain on change in fair value of derivatives offsetting higher operating expenses of $228,095 (up from $129,159). Total assets declined sharply to $3,382 from $119,922, primarily from deconsolidation of discontinued operations including Jubilee, while total liabilities fell to $349,258 from $1,497,644 and stockholders' deficit improved to $(345,876) from $(1,377,722) amid massive common stock issuances diluting shares from 1,049,794 to 63,994,148. Cash remained nearly flat at $3,382 versus $3,629, with net cash used in operations at $150,524.

• ·Convertible notes payable – related party net: $16,402 (2025) vs $74,501 (2024)
• ·Derivative liability: $102,670 (2025) vs $510,154 (2024)
• ·Common stock issued for conversion of debt: $939,403 (2025) vs $5,003 (2024)
• ·NOL carried forward increased to $4,049,008 from $3,922,060
• ·12 warrants outstanding at $500 exercise price as of Dec 31, 2025

28-04-2026

AvalonBay Communities reported Q1 2026 EPS of $2.33, up 40.4% YoY from $1.66, primarily due to real estate gains, while FFO per share declined 2.2% to $2.72 and Core FFO per share remained flat at $2.83 versus prior year. Same Store Residential revenue increased 1.6% to $703,976,000, but operating expenses rose 4.7% to $224,039,000, limiting NOI growth to 0.2% at $479,937,000. The company completed one development (Avalon Lake Norman for $102,000,000), started two more totaling $188,000,000 estimated cost, sold three communities for $340,750,000, repurchased $198,480,000 in stock, and issued Q2 2026 guidance while reaffirming full-year Core FFO outlook but lowering EPS expectations.

• ·25 wholly-owned development communities under construction with 8,673 apartment homes and 69,000 square feet of commercial space for estimated $3,390,000,000 total capital cost.
• ·Received $17,580,000 repayment on one SIP mezzanine loan; new $15,000,000 commitment in April 2026, both for Metro NY/NJ multifamily projects.
• ·Annualized Net Debt-to-Core EBITDAre of 4.8 times; Unencumbered NOI of 95% for Q1 2026.
• ·$914,354,000 remaining capacity under 2026 Stock Repurchase Program.
• ·Q2 2026 guidance: EPS $1.23-$1.33, FFO per share $2.68-$2.78, Core FFO per share $2.72-$2.82; full-year Core FFO reaffirmed, EPS outlook $5.92-$6.42.
• ·Conference call on April 28, 2026 at 1:00 PM ET.

28-04-2026

Zimmer Biomet Holdings, Inc. (ZBH) announced that Suketu Upadhyay, Chief Financial Officer and Executive Vice President, Finance, Operations and Supply Chain, will depart effective April 28, 2026, for a new professional opportunity after seven years with the company. Paul Stellato, current Controller and Chief Accounting Officer, has been appointed as interim CFO while a search for a permanent successor is conducted. Chairman, President and CEO Ivan Tornos expressed gratitude for Upadhyay's contributions and confidence in Stellato's ability to ensure continuity.

• ·Paul Stellato joined Zimmer Biomet in May 2022 and previously held roles at Xylem Inc. and ITT Corporation.
• ·Stellato holds a BS in Accountancy from Villanova University, an MBA from NYU Stern, and is a CPA.

28-04-2026

LG Display's total revenue declined 3.0% YoY to W25,810 billion (US$17,867 million) in 2025 from W26,615 billion in 2024, driven by drops in China (-8.6%), Americas (-13.7%), and Europe (-11.8%), though Asia ex-China grew 40.7%. Despite the sales decline, the company swung to a profit of W304 billion (1.2% margin, US$210 million) from a loss of W2,409 billion in 2024, with gross profit margin improving to 13.1% from 9.7% amid lower costs. Regional and product mixes showed mixed performance, with IT products nearly flat (+0.9%) and TV panels down 19.8% YoY.

• ·Cost of sales as % of revenue improved to 86.9% in 2025 from 90.3% in 2024.
• ·Research and development expenses: W1,411 billion in 2025 (5.5% of revenue).
• ·Total selling, general, and administrative expenses declined to W1,449 billion in 2025 from W1,688 billion in 2024.
• ·Unsecured bank borrowings: W11,245 billion total.
• ·Most subsidiaries are 100% owned, with L&T Display Technology (Fujian) Ltd. at 51% and LG Display High-Tech (China) Co., Ltd. at 70%.

28-04-2026

The 2026 Proxy Statement for Universal Health Realty Income Trust (UHT), filed April 28, 2026, discloses beneficial share ownership as of March 31, 2026, with major holders BlackRock, Inc. (1,989,533 shares, 14.34%), The Vanguard Group Inc. (1,648,457 shares, 11.88% based on prior filing amid disaggregation), and Universal Health Services, Inc. (787,543 shares, 5.68%). All trustees and executive officers as a group beneficially own 362,486 shares (2.61%), with no shares pledged. Proposal No. 1 seeks shareholder approval to elect Alan B. Miller and Robert F. McCadden as Class I Trustees for three-year terms expiring at the 2029 Annual Meeting.

• ·No outstanding options, warrants or rights under equity compensation plans as of December 31, 2025.
• ·Includes restricted shares for insiders awarded in 2024 (vesting 2026) and 2025 (vesting 2027).
• ·Board of Trustees has staggered three-year terms; majority must be Independent Trustees.
• ·Vanguard's 11.88% based on September 30, 2024 filing; recent 13G/A notes disaggregation of ownership.

28-04-2026

Avery Dennison reported first quarter 2026 net sales of $2,298.5 million, up 7.0% YoY, driven by 11.4% growth in Materials Group to $1,649.3 million, though Solutions Group sales declined 2.8% to $649.2 million and organic sales grew only 1.1%. Adjusted EPS increased 7.4% to $2.47, with adjusted free cash flow of $104.4 million, while the company returned $133 million to shareholders via dividends and repurchases. Second quarter 2026 adjusted EPS guidance is $2.43 to $2.53.

• ·Net debt to adjusted EBITDA ratio of 2.4x at Q1 2026 end.
• ·Adjusted operating margin for Materials Group 15.4% (down 20 bps YoY); for Solutions Group 9.0% (down 120 bps YoY).
• ·Q1 2026 adjusted tax rate of 26.2%.
• ·Q1 2026 pre-tax restructuring charges of $16 million.

28-04-2026

Invesco Ltd. reported $21.8 billion in net long-term inflows for Q1 2026, up from $19.1 billion in Q4 2025 and $17.6 billion in Q1 2025, though offset by $10.8 billion outflows from QQQ and $2.4 billion from Fundamental Equities, resulting in ending AUM of $2,159.5 billion (down 0.5% QoQ but up 17.1% YoY). Operating revenues increased 14.1% YoY to $1,744.5 million with adjusted diluted EPS of $0.57 (up 29.5% YoY), but adjusted operating income declined 4.8% QoQ to $436.0 million and net revenues were flat at 0.4% QoQ growth. The company repurchased $40 million in shares, redeemed $500 million senior notes, and raised its quarterly common dividend to $0.215 per share.

• ·Redeemed $500 million senior notes maturing January 15, 2026; credit facility balance $1.1 billion as of March 31, 2026.
• ·Net long-term outflows: QQQ $10.8 billion, Fundamental Equities $2.4 billion.
• ·Money market inflows $11.5 billion; total net flows $33.3 billion.
• ·Annualized long-term organic growth rate 4.4%.
• ·Common shares outstanding 443.3 million; diluted 455.3 million.
• ·Dividends paid: common $95.3 million, preferred $38.2 million.

28-04-2026

CECO Environmental reported Q1 2026 results showing robust top-line growth with orders up 97% YoY to $449.5 million and backlog hitting a record $1,035.1 million (up 72%), alongside revenue growth of 17% to $205.9 million and adjusted EBITDA up 46% to $20.4 million. However, the company recorded a net loss of $(0.4) million (down 101% from prior profit), operating income down 97% to $1.9 million, and free cash flow of $(15.7) million (down 4%). CECO raised FY2026 guidance to revenue of $940-$1,000 million (up ~25% at midpoint) and adjusted EBITDA of $120-$140 million (up ~45%), while providing an update on its pending merger with Thermon expected to close in June 2026.

• ·Book-to-bill ratio of 2.2 in Q1 2026.
• ·Largest ever Natural Gas Power order booked in April 2026.
• ·Thermon stockholder vote expected May 27, 2026; merger close expected June 2026.
• ·Expected $40 million in cost synergies from Thermon merger.
• ·Gross margin of 31.0% in Q1 2026; expected to improve in H2 2026 due to higher margin backlog.
• ·Conference call scheduled for April 28, 2026 at 8:30 a.m. ET.

28-04-2026

Avalo Therapeutics, Inc. (Nasdaq: AVTX) entered into a Milestone Buyout Option and Amendment Agreement with former AlmataBio securityholders, paying $2.25 million for an option exercisable within 90 days to pay an additional $5.125 million in cash or shares instead of a $15 million contingent milestone payment due upon dosing the first patient in a Phase 3 trial. This agreement relates to Avalo's prior acquisition of AlmataBio in March 2024 and reduces potential future obligations. No negative financial impacts or declines were disclosed.

• ·Prior acquisition of AlmataBio occurred in March 2024.
• ·Lead asset abdakibart (AVTX-009) is in Phase 2 trial for hidradenitis suppurativa (HS).

28-04-2026

Coca-Cola reported strong Q1 2026 results with global unit case volume up 3%, net revenues up 12% to $12.5 billion, organic revenues up 10%, operating income up 19%, and comparable EPS up 18% to $0.86, alongside operating margin expansion to 35.0% from 32.9%. The company gained value share in total NARTD beverages globally. However, Asia Pacific operating income declined 14% (comparable currency neutral down 17%) with price/mix down 6%, juice/dairy/plant-based beverages declined 1%, and coffee volume was flat.

• ·Company gained value share in total NARTD beverages across most regions, even in Asia Pacific.
• ·Coca-Cola Zero Sugar grew 13% globally.
• ·Tea grew 38% globally.
• ·Pending sale of CCBA expected in H2 2026, impacting guidance.
• ·Six additional days in Q1 contributed to concentrate sales outpacing volume by 5 points globally.
• ·Updated FY 2026 underlying effective tax rate estimated at 19.9%.
• ·Expected 1-2% currency tailwind for comparable net revenues FY 2026.

28-04-2026

S&P Global reported first-quarter 2026 revenue of $4.171 billion, up 10% YoY driven by Ratings, Indices, and Market Intelligence, with GAAP net income up 28% to $1.395 billion and adjusted diluted EPS up 14% to $4.97. GAAP operating margin expanded 620 basis points to 48.0% and adjusted operating margin rose 100 basis points to 51.8%, while subscription revenue grew 6% YoY. The company repurchased $1 billion in shares, remains on track for Mobility division separation and a geoscience divestiture, but updated 2026 guidance with reported revenue growth narrowed to 6.3%-8.3% (30 bps lower due to FX) and interest expense $10 million higher.

• ·2026 reported revenue growth guidance: 6.3% to 8.3%; organic constant currency: 6.0% to 8.0%.
• ·2026 adjusted diluted EPS guidance: $19.40 to $19.65.
• ·Mobility Global Investor Day: May 12, 2026.
• ·Geoscience divestiture expected to close H2 2026 or early 2027.
• ·Quarterly cash dividend: $0.97 per share.
• ·Conference call: April 28, 2026 at 8:30 a.m. EDT.

28-04-2026

Exodus Movement, Inc. exercised its rights as a secured lender to appoint a receiver in the United Kingdom over W3C Corp. subsidiaries Monavate Holdings Limited, Monavate Limited, and Baanx Ltd. due to W3C's failure to repay amounts due under a term loan facility after demand for immediate repayment. The receiver intends to conduct a sale process of the subsidiaries' shares, with Exodus expecting to participate.

• ·Filing items: 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits).
• ·Date of earliest event reported: April 28, 2026.

28-04-2026

Cabaletta Bio, Inc. (CABA) issued additional proxy materials (DEFA14A) for its Annual Meeting of Stockholders on June 9, 2026, at 9:00 AM ET virtually, for holders of record as of April 20, 2026. Proposals include electing Class I directors Scott Brun, M.D. and Shawn Tomasello, MBA (Proposal 1), ratifying Ernst & Young LLP as auditors for FY 2026 (Proposal 2), amending the 2019 Stock Option and Incentive Plan (Proposal 3), increasing authorized common shares from 300,000,000 to 600,000,000 (Proposal 4), advisory approval of NEO compensation (Proposal 5), and adjournment if needed for Proposals 3/4 (Proposal 6). The Board recommends FOR all proposals; full materials available at www.proxydocs.com/CABA.

• ·Paper proxy requests due by May 29, 2026
• ·Fiscal year for audit ratification ends December 31, 2026
• ·Directors elected to serve until 2029 annual meeting

28-04-2026

Wave Life Sciences reported Q1 2026 financial results with revenue of $38.2 million, up significantly from $9.2 million in Q1 2025, and a reduced net loss of $26.1 million compared to $46.9 million prior year, supported by a strong cash position of $544.6 million providing runway into 3Q 2028. However, cash decreased from $602.1 million at year-end 2025, R&D expenses rose to $47.4 million from $40.6 million, and G&A expenses increased to $22.1 million from $18.4 million YoY. Pipeline progress includes FDA acceptance for Phase 2a INLIGHT trial of WVE-007 initiating in 2Q 2026, data presentations for WVE-006 at ATS in May 2026, and upcoming milestones for WVE-008 and WVE-N531.

• ·Phase 2a INLIGHT trial accepted by FDA for individuals with BMI 35-50 kg/m2, on track to initiate 2Q 2026.
• ·Data from RestorAATion-2 400 mg monthly and 600 mg single dose cohorts to be presented at ATS investor webcast May 18, 2026.
• ·Regulatory feedback on accelerated approval for WVE-006 expected mid-2026.
• ·CTA for WVE-008 on track for 2026; NDA for WVE-N531 on track for 2026.
• ·Phase 1 INLIGHT additional data from 600 mg SAD cohort expected 2026.